

PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

[View Online](#)

[1]

Atwood, B.K. et al. 2012. CB2: Therapeutic target-in-waiting. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 38, 1 (Jul. 2012), 16–20. DOI:<https://doi.org/10.1016/j.pnpbp.2011.12.001>.

[2]

Balon, R. 2006. Mood, anxiety, and physical illness: body and mind, or mind and body? *Depression and Anxiety*. 23, 6 (2006), 377–387. DOI:<https://doi.org/10.1002/da.20217>.

[3]

Brisbare-Roch, C. 2007. Promotion of sleep by targeting the orexin system in rats, dogs and humans. 13, 2 (2007), 150–155.

[4]

Carlos H. Schenck, M.W.M. 2005. Insights from studying human sleep disorders. 437, 7063 (2005), 1279–1285.

[5]

Carvalho, A.F. and Van Bockstaele, E.J. 2012. Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 38, 1 (Jul. 2012), 59–67. DOI:<https://doi.org/10.1016/j.pnpbp.2012.01.008>.

[6]

Cera, N. et al. 2014. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE. 9, 9 (Sep. 2014). DOI:<https://doi.org/10.1371/journal.pone.0107145>.

[7]

Cryan, J.F. and Kaupmann, K. 2005. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences. 26, 1 (Jan. 2005), 36–43. DOI:<https://doi.org/10.1016/j.tips.2004.11.004>.

[8]

Eric J. Olson, K.R. 2013. Management of common sleep disorders. 88, 4 (2013), 231–238.

[9]

Freund, T.F. 2003. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences. 26, 9 (Sep. 2003), 489–495. DOI:[https://doi.org/10.1016/S0166-2236\(03\)00227-3](https://doi.org/10.1016/S0166-2236(03)00227-3).

[10]

H. Attarian, O.A. Treatment of disorders of hypersomnolence. 16, 9, 302–302.

[11]

Hill, A.J. et al. 2012. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics. 133, 1 (Jan. 2012), 79–97. DOI:<https://doi.org/10.1016/j.pharmthera.2011.09.002>.

[12]

Holmes, A. et al. 2003. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences. 24, 11 (Nov. 2003), 580–588. DOI:<https://doi.org/10.1016/j.tips.2003.09.011>.

[13]

Hoyer, D. and Jacobson, L.H. 2013. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? *Neuropeptides*. 47, 6 (Dec. 2013), 477–488.
DOI:<https://doi.org/10.1016/j.npep.2013.10.009>.

[14]

Kalueff, A.V. and Nutt, D.J. 2007. Role of GABA in anxiety and depression. *Depression and Anxiety*. 24, 7 (2007), 495–517. DOI:<https://doi.org/10.1002/da.20262>.

[15]

Kilduff, T.S. and Peyron, C. 2000. The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. *Trends in Neurosciences*. 23, 8 (Aug. 2000), 359–365. DOI:[https://doi.org/10.1016/S0166-2236\(00\)01594-0](https://doi.org/10.1016/S0166-2236(00)01594-0).

[16]

Levine, J. et al. 2001. Anxiety disorders and major depression, together or apart. *Depression and Anxiety*. 14, 2 (2001), 94–104. DOI:<https://doi.org/10.1002/da.1051>.

[17]

Luscher, B. et al. 2011. The GABAergic deficit hypothesis of major depressive disorder. *Molecular Psychiatry*. 16, 4 (Apr. 2011), 383–406.
DOI:<https://doi.org/10.1038/mp.2010.120>.

[18]

Mahowald, M.W. and Schenck, C.H. 1992. Dissociated states of wakefulness and sleep. *Neurology*. 42 Suppl. 6, (1992), 44–52.

[19]

Mark W. Mahowald MD 2007. Pathophysiologic mechanisms in REM sleep behavior disorder. *Current Neurology and Neuroscience Reports*. 7, Issue 2 (Mar. 2007), 167–172.

DOI:<https://doi.org/10.1007/s11910-007-0013-7>.

[20]

N.P. Robertson, K.J.P. 2014. Narcolepsy: environment, genes and treatment. 261, 8 (2014), 1644–1646.

[21]

Saper, C.B. and Scammell, T.E. 2013. Emerging therapeutics in sleep. *Annals of Neurology*. 74, 3 (Aug. 2013), 435–440. DOI:<https://doi.org/10.1002/ana.24000>.

[22]

Smith, K.S. and Rudolph, U. 2012. Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. *Neuropharmacology*. 62, 1 (Jan. 2012), 54–62. DOI:<https://doi.org/10.1016/j.neuropharm.2011.07.026>.

[23]

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy:
https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.

[24]

Stores, G. 2003. Medication for sleep-wake disorders. *Archives of Disease in Childhood*. 88, 10 (Oct. 2003), 899–903. DOI:<https://doi.org/10.1136/adc.88.10.899>.

[25]

Strange, P.G. 1992. *Brain biochemistry and brain disorders*. Oxford University Press.